The Telegraph reported that diranersen is given twice a year and uses gene-silencing technology to reduce tau production in the brain. Dr Richard Oakley said it is given via lumbar puncture. The CELIA trial results, announced in Boston, showed that patients receiving low-dose diranersen had 54 per cent less decline on a test of memory and thinking over almost two years, according to the Telegraph.
Dr Richard Oakley, associate director for research and innovation at Alzheimer's Society, said: "Alzheimer's is a complex disease, but we know that the build-up of two proteins in the brain, amyloid and tau, plays an important role in its development. While many recent scientific advances have focused on amyloid, we urgently need treatments that tackle Alzheimer's in different ways. Diranersen is a particularly interesting therapy because it targets tau at its source. It works a bit like a gene 'off-switch', reducing the amount of tau the brain produces rather than trying to clear it once it has already built up."
He added: "The latest clinical trial results for this drug are very encouraging. They suggest that diranersen effectively reduces the build-up of tau in the brain, and the treatment's ability to slow worsening of memory and thinking problems increases over two years. If these promising findings are confirmed in the upcoming phase three trial, a significant new treatment option for early Alzheimer's disease could be within touching distance."
British patients are asking to join the next trial, with UK recruitment expected to start in the spring, the Telegraph said.
